Background: The current Canadian guidelines endorse the use of MgSO 4 for treatment of eclampsia and for prophylaxis in severe preeclampsia.
Background
With preeclampsia complicating 2-8% of pregnancies and eclampsia occurring in 4-6 per 10,000 live births, 1 these hypertensive disorders of pregnancy remain among the principal causes of maternal and perinatal morbidity and mortality. In an attempt to provide a clear approach to the diagnosis, evaluation, and management of the different hypertensive disorders of pregnancy, the Society of Obstetricians and Gynaecologists of Canada (SOGC) endorsed a series of clinical practice guidelines (hereafter ''the guidelines'') based on the best available scientific evidence. 2 The guidelines describe preeclampsia as a hypertensive disorder of pregnancy characterized by the presence of proteinuria or the presence of one or more ''adverse conditions'' (full list of adverse conditions in Magee et al. 2008 ). Severe preeclampsia is further defined as preeclampsia with: onset before 34 weeks' gestation, heavy proteinuria, or the presence of one or more adverse conditions. 2 A small proportion of patients with preeclampsia go on to develop eclampsia (0.5%-3%), 3, 4 which has been associated with persistent visual and neurological sequelae that may carry long-term consequences for the mother. [5] [6] [7] [8] Forty percent of deaths from eclampsia are thought to be preventable. 9 The guidelines recommend the use of magnesium sulfate (MgSO 4 ) for prophylaxis in patients with severe preeclampsia (I-A 10, 11 ) and for the treatment of eclampsia (I-A). 2 In developed countries, MgSO 4 administration for non-severe preeclampsia may also be considered (I-B). 2 Given the demonstrated importance of MgSO 4 use in preventing and treating eclampsia 3, 12 and a perceived lack of uniformity in our institution's use of MgSO 4 , we felt it was important to undertake an audit of our practices. The primary objective of this study was to evaluate if the use of MgSO 4 for treating severe preeclampsia and eclampsia at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) conforms to the current Canadian guidelines. In the event of imperfect compliance, we aimed to identify the criteria influencing a clinician's decision to administer or withhold MgSO 4 for the treatment of severe preeclampsia.
Methods
This is a descriptive, retrospective study based on the information provided in patient charts obtained from the CIRESSS (Centre infor-matise´de recherche e´valuative en services et soins de sante´) database, where hospital summary sheets are maintained. The study protocol was approved by our institution's Research Ethics Board.
Sample
The following charts were requested from the CIRESSS database: 50 most recent consecutive cases of non-severe preeclampsia between 1 January 2009 and 22 May 2010; 50 most recent consecutive cases of severe preeclampsia between 1 January 2009 and 22 May 2010. We also requested all cases of eclampsia from 1 January 2002 (publication of the MAGPIE trial 3 ) to 31 January 2012 to specifically evaluate the current practices of clinicians who are faced with this rare occurrence at our institution. This sample size was used based on the resources available for the extensive chart review needed to attain the primary objective. We excluded ''preeclampsia superimposed on pre-existing hypertension'' to reduce the impact of confounding factors in the management of these patients whose diagnosis and evaluation of severity are especially difficult. Patient characteristics, presence of adverse conditions (10 of the 18 defined by the guidelines 2 ), and management modalities were recorded using chart review. Preeclampsia severity diagnoses were verified carefully by the research team to identify cases of severe preeclampsia initially misdiagnosed as non-severe, e.g. cases in which the presence of one or more adverse conditions was recorded in the chart, yet the patient was diagnosed with non-severe preeclampsia. Current practice was then compared to the guidelines for MgSO 4 use in eclampsia and preeclampsia management.
Statistical analysis
Chi-square and Fisher's exact tests were used to identify the factors influencing a clinician's decision to administer or withhold prophylactic MgSO 4 by comparing patients with severe preeclampsia, initially accurately diagnosed, that did and did not receive MgSO 4 . To determine what factors most influenced clinicians' preeclampsia severity diagnoses, we used Chi-square and Fisher's exact tests to compare the characteristics of patients with severe preeclampsia with correct and incorrect initial diagnoses. A binary logistic regression analysis with backward stepwise model selection was then used to further identify factors associated with preeclampsia severity diagnoses.
Results

Preeclampsia
Of the 100 cases available for review, 34 were rejected for presenting hypertensive disorders without preeclampsia, and one file was rejected due to a classification error. Figure 1 depicts the classification of the remaining 65 files according to preeclampsia severity and highlights the high rate of preeclampsia severity misdiagnosis; 23 severe cases were incorrectly diagnosed as non-severe (misdiagnosis rate of 35%). After correcting these diagnoses, 59/65 (91%) of the preeclampsia cases met the guidelines' criteria for diagnosis as ''severe.'' Table 1 provides additional information about the patients including symptoms and management.
Among the 59 patients meeting the criteria for severe preeclampsia and in whom prophylactic MgSO 4 would have been indicated, 25 (42%) received MgSO 4 . All the patients who received the medication were among the 36 cases initially correctly diagnosed as ''severe'' (25/36 (69%); Figure 1 ). No other patients received MgSO 4 prophylactically and none had contraindications related to MgSO 4 . Table 2 compares the characteristics of women diagnosed with severe preeclampsia, exclusively those initially correctly diagnosed as such (n ¼ 36), who received MgSO 4 to those that did not. None of the comparisons yielded statistically significant differences.
Univariate comparison of the characteristics of patients correctly and incorrectly diagnosed with severe preeclampsia revealed that severe hypertension (and use of antihypertensive medication), elevated creatinine levels, and hyperreflexia were significantly associated with an accurate diagnosis (Table 3 ). Furthermore, as the number of concurrent signs included in the guidelines as ''adverse conditions'' increased, the proportion of patients correctly diagnosed as severely preeclamptic also increased (p ¼ 0.011). A similar pattern was tested for in concurrent symptoms identified as adverse conditions, but did not reach statistical significance (p ¼ 0.676).
Among the patient characteristics presented in Table 3 , the final logistic regression model retained severe hypertension and thrombocytopenia as factors contributing significantly to an accurate diagnosis of ''severe preeclampsia''; elevated serum creatinine was retained as well, though did not quite attain statistical significance (see Table 4 for significance, odds ratios, and 95% confidence intervals).
Eclampsia
Eight cases of eclampsia were attended to at the CHUS in the selected timeframe ( Table 1) . None of the patients were being treated prophylactically with MgSO 4 at the time of the seizure. Seven patients were treated with MgSO 4 after seizure. The remaining patient, whose diagnosis was uncertain at the time, did not receive anticonvulsants, but was subsequently diagnosed with eclampsia by exclusion of other diagnoses. Three of the eight eclampsia cases presented to the hospital during or just after a seizure. Three other cases presented episodes of severe hypertension or other adverse conditions indicative of severe preeclampsia before the seizure.
Discussion
Our report reveals an underutilization of MgSO 4 prophylactically in women with severe preeclampsia despite what is clearly recommended in the guidelines. A high proportion of erroneous diagnoses is likely to However, we estimate that of the five patients that were in the hospital prior to starting convulsions, eclampsia could have been prevented in three of these patients by administering prophylactic MgSO 4 , given that adverse conditions were present before the seizure. In a Canadian study, the incidence of eclampsia was shown to have declined by 50% between 2003 and 2010. 13 While improved antenatal care, premature delivery in cases of preeclampsia, and improved maternal and neonatal intensive care are believed to have contributed to this decline, the authors presume that the main factor responsible was the increased prophylactic use of MgSO 4 in women with severe preeclampsia. 13 Our study was limited statistically as a result of 35% of cases being rejected outright due to the extraction of patient files classified under code O13 of the 2010 International Classification of Diseases (uncomplicated gestational hypertension). In combination with the high misdiagnosis rate, it was difficult to pursue additional statistical avenues; however, it is clear that our use of MgSO 4 in patients with severe preeclampsia was suboptimal.
Conclusion
In order to improve our personnel's ability to accurately diagnose preeclampsia severity and increase their use of MgSO 4 when appropriate, a MgSO 4 protocol and informative poster were developed emphasizing the guidelines' criteria for severity, as well as providing recommendations for using MgSO 4 to treat severe preeclampsia in the maternity ward. Also, a similar analysis will be repeated after an adjustment period to see whether the measures undertaken have a positive impact on diagnostic accuracy and MgSO 4 prescription when indicated.
